{"nctId":"NCT04607980","briefTitle":"A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","startDateStruct":{"date":"2020-11-11","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":563,"armGroups":[{"label":"Treatment Group A (ABP 654)","type":"EXPERIMENTAL","interventionNames":["Drug: ABP 654"]},{"label":"Treatment Group B (Ustekinumab - ABP 654)","type":"EXPERIMENTAL","interventionNames":["Drug: ABP 654","Drug: Ustekinumab"]}],"interventions":[{"name":"ABP 654","otherNames":[]},{"name":"Ustekinumab","otherNames":["Stelara®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n* Stable moderate to severe plaque psoriasis for at least 6 months\n* Baseline score of PASI \\>= 12, involvement of \\>= 10% BSA, and sPGA \\>= 3 at screening and at baseline\n* Candidate for phototherapy or systemic therapy\n* Previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional anti-psoriatic systemic therapy\n* Female participants should have negative serum pregnancy test during screening and a negative urine pregnancy test at baseline\n* No known history of latent or active tuberculosis (TB), and has a negative test for TB during screening (with negative purified protein derivative (PPD), and Negative Quantiferon®/T-spot test)\n* Participants with a positive purified protein derivative and a history of Bacillus Calmette-Guérin (BCG) vaccination are allowed with a negative Quantiferon®/T-spot®\n* Participants with a positive PPD test (without history of BCG vaccination) or participants with a positive or indeterminate Quantiferon®/T-spot test are allowed if they have all of the following:\n\n  * No symptoms per TB worksheet provided by the sponsor\n  * Documented history of adequate prophylaxis initiation prior to receiving investigational product (IP) in accordance with local recommendations\n  * No known exposure to a case of active TB after most recent prophylaxis\n  * No evidence of active TB on chest radiograph within 3 months prior to the first dose of IP\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Skin disease related conditions such as, Erythrodermic psoriasis (PsO), pustular PsO, guttate PsO, medication induced PsO, or other skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of IP on PsO\n* Participant has an active infection, recurrent or chronic infections, serious infection or history of infections\n* Known history of human immunodeficiency virus\n* Hepatitis B surface antigen or hepatitis C virus antibody positivity at screening\n* Uncontrolled, clinically significant systemic disease such as uncontrolled diabetes mellitus, cardiovascular disease, renal disease, liver disease, or hypertension\n* Moderate to severe heart failure (New York Heart Associate class III/IV)\n* Known hypersensitivity to the IP or to any of the excipients\n* Any abnormal laboratory parameters at screening, as defined in protocol\n* Previous treatment with any agent specifically targeting interleukin (IL)-12 or IL-23\n* Received biologic treatment for psoriasis within the previous month or 5 drug half-lives prior to randomization\n* Received non-biologic systemic psoriasis therapy within 4 weeks prior to randomization\n* Received Ultra-violet A (UVA) phototherapy (with or without psoralen) or excimer laser within 4 weeks prior to randomization, or ultra-violet B (UVB) phototherapy within 2 weeks prior to randomization\n* Received topical psoriasis treatment within 2 weeks prior to randomization (exception: upper mid-strength to least potent \\[class III to VII\\] topical steroids permitted on the palms, soles, face, and intertriginous areas; bland emollients)\n* Received live viral or live bacterial vaccination within 2 weeks prior to randomization\n* Received BCG vaccination within 1 year prior to randomization\n* Other investigational procedures within 4 weeks prior to randomization and during the study\n* Participants not agreeing to follow protocol defined contraceptives procedures\n* Participants likely not to be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PASI Percent Change From Baseline to Week 12","description":"The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale \\[0 = clear; 1-4 = increasing severity\\]) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. Higher scores represent worse symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.92","spread":"19.872"},{"groupId":"OG001","value":"81.91","spread":"19.611"}]}]}]},{"type":"SECONDARY","title":"PASI Percent Change at Other Timepoints","description":"The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale \\[0 = clear; 1-4 = increasing severity\\]) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. Higher scores represent worse symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.15","spread":"23.587"},{"groupId":"OG001","value":"42.40","spread":"24.536"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.88","spread":"18.704"},{"groupId":"OG001","value":"85.86","spread":"19.953"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.41","spread":"14.228"},{"groupId":"OG001","value":"88.18","spread":"18.771"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.53","spread":"11.038"},{"groupId":"OG001","value":"74.12","spread":"13.826"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"93.60","spread":"9.738"},{"groupId":"OG003","value":"94.22","spread":"8.296"},{"groupId":"OG004","value":"95.10","spread":"8.529"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.33","spread":"15.563"},{"groupId":"OG001","value":"78.42","spread":"14.733"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.80","spread":"14.760"},{"groupId":"OG001","value":"77.46","spread":"18.109"},{"groupId":"OG002","value":"92.54","spread":"11.808"},{"groupId":"OG003","value":"93.90","spread":"8.987"},{"groupId":"OG004","value":"93.23","spread":"16.029"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PASI 75 Response Throughout the Study","description":"Reduction in disease was measured by PASI score. The PASI 75 response is a 75% or greater improvement (reduction in disease \\[PASI 75\\]) from baseline in PASI score. The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale \\[0 = clear; 1-4 = increasing severity\\]) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. Higher scores represent worse symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":null},{"groupId":"OG001","value":"70.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"80.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null},{"groupId":"OG001","value":"82.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","spread":null},{"groupId":"OG001","value":"55.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"94.7","spread":null},{"groupId":"OG003","value":"95.7","spread":null},{"groupId":"OG004","value":"94.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"58.8","spread":null},{"groupId":"OG002","value":"89.5","spread":null},{"groupId":"OG003","value":"92.3","spread":null},{"groupId":"OG004","value":"92.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PASI 100 Response Throughout the Study","description":"Reduction in disease was measured by PASI score. The PASI 100 response is a 100% improvement (reduction in disease \\[PASI 100\\]) from baseline in PASI score. The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale \\[0 = clear; 1-4 = increasing severity\\]) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. Higher scores represent worse symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"26.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"31.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"44.5","spread":null},{"groupId":"OG003","value":"41.9","spread":null},{"groupId":"OG004","value":"46.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"14.7","spread":null},{"groupId":"OG002","value":"47.0","spread":null},{"groupId":"OG003","value":"42.7","spread":null},{"groupId":"OG004","value":"44.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With sPGA Responses (0/1) at Week 12 and Week 52","description":"The sPGA is a 6-point scale ranging from 0 (clear) to 5 (very severe) used to measure the severity of disease (induration, scaling, and erythema). A sPGA response was defined as a sPGA value of clear (score 0) or almost clear (score 1). Higher scores represent worse symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"52.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"35.3","spread":null},{"groupId":"OG002","value":"71.3","spread":null},{"groupId":"OG003","value":"70.9","spread":null},{"groupId":"OG004","value":"78.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage of BSA Affected With Psoriasis at Week 12 and Week 52","description":"The percentage of BSA affected was estimated by assuming that the participant's palm, excluding the fingers and thumb, represents roughly 1% of the body's surface.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.8","spread":"14.32"},{"groupId":"OG001","value":"-17.2","spread":"14.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.6","spread":"14.72"},{"groupId":"OG001","value":"-21.6","spread":"16.89"},{"groupId":"OG002","value":"-24.7","spread":"14.81"},{"groupId":"OG003","value":"-22.8","spread":"13.86"},{"groupId":"OG004","value":"-22.5","spread":"14.11"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"TEAEs were summarized by actual treatment received. For each category, participants were included only once, even if they experienced multiple events in that category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"44","spread":null},{"groupId":"OG004","value":"40","spread":null},{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Events of Interests (EOIs)","description":"The EOIs pre-specified for this study included serious systemic hypersensitivity reactions, facial palsy, pustular psoriasis, erythrodermic psoriasis, serious infections (including mycobacterial and salmonella infections), malignancy, cardiovascular events, reversible posterior leukoencephalopathy syndrome, serious depression including suicidality, and venous thromboembolism.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Developing Anti-drug Antibodies (ADAs) to ABP 654","description":"A participant was considered to have developed ADAs if they:\n\n* had a positive post-baseline binding or neutralizing antibody result with a negative or no result at Baseline or\n* had a positive post-baseline binding or neutralizing antibody result with a negative or no result prior to the first dose in the post Week 28 study period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"104","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":280},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Proteinuria"]}}}